News

Serpin Pharma and HekaBio Sign Term Sheet for Groundbreaking Neuropathy Treatment

Serpin Pharma, a Virginia-based biopharmaceutical company, and HekaBio, headquartered in Tokyo, Japan, have signed a term sheet to develop and commercialize SP163M, a novel peptide drug for preventing chemotherapy-induced peripheral neuropathy (CIPN).

SP163M, a groundbreaking discovery by Serpin Pharma, is set to revolutionize pain management. This novel therapy protects nerves from the damaging effects of neurotoxic chemotherapy drugs, facilitates nerve repair, and alleviates pain. For cancer patients suffering from neuropathy as a side effect of chemotherapy, SP163M offers a critically needed solution. The development of neuropathy often necessitates reducing planned chemotherapy regimens, which may affect cancer outcomes. Preventative therapy could be lifesaving for these patients.

As part of this strategic alliance, HekaBio will spearhead the commercialization of SP163M in critical markets, including Japan, Korea, Taiwan, Australia, ASEAN, the Middle East (excluding Israel), and North Africa. This collaboration integrates Serpin Pharma’s prowess in peptide therapeutics with HekaBio’s strong presence in the Asian and Australian markets.  HekaBio’s strategic investment in Serpin Pharma, along with milestone and royalty payments, underscores the mutual commitment to the success of this innovative therapy.

Dr. Cohava Gelber, Founder, Executive Chairperson, and CEO of Serpin Pharma, expressed enthusiasm about the collaboration: “We are thrilled to partner with HekaBio to bring this revolutionary therapy to cancer patients. SP163M can potentially significantly improve the quality of life for those undergoing chemotherapy.”

Rob Claar, the CEO of HekaBio, stated: “Our collaboration with Serpin Pharma is inspiring. By combining our complementary capabilities, we aim to deliver a game-changing treatment option for cancer patients suffering from CIPN.”

This partnership marks a significant step towards addressing the unmet medical needs for effective CIPN treatments. As the companies advance their development and commercialization plans, cancer patients in the specified regions may soon have access to this innovative therapy.

Read more here.

Recent News

07/19/2024

Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing

Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide

07/15/2024

Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity

AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients. Omega3 lipids called polyunsaturated fatty acids (PUFAs) that are found in microscopic shrimp-like crustaceans called Krill from the waters around Antarctica are key to maintaining a low inflammatory state.  Some

07/15/2024

Inorganic Ventures acquires PURE Analytical Laboratories, Combining Unique Capabilities for Precision Manufacturing

Two privately held specialty chemical firms that provide high-purity materials and services for chemical applications, from renewable energy to food and beverages and consumer safety, are combining their capabilities to serve new and expanding precision markets. IV Labs Inc., the parent company of Inorganic Ventures, has acquired PURE Analytical Laboratories, one of the few companies that